Literature DB >> 14686498

Prevalence and clinical significance of hepatitis C virus infection in Thai patients with thalassemia.

Wanchai Wanachiwanawin1, Pairoj Luengrojanakul, Pornpan Sirangkapracha, Wattana Leowattana, Suthat Fucharoen.   

Abstract

Hepatitis C virus (HCV) infection is a common cause of liver disease in thalassemia major patients in Western, especially Mediterranean, countries. Its significance in thalassemic patients from Southeast Asia has not been critically evaluated. In this report, we describe our study of the prevalence of HCV infection among Thai patients with thalassemia. The relationships of the infection to blood transfusion and the infection's effects on liver function have also been determined. Of the 104 patients studied, 21 (20.2%) tested positively by enzyme immunoassay for anti-HCV antibody, whereas only 2 patients (2%) had the hepatitis B surface antigen. There was no significant relationship between the presence of anti-HCV antibodies and the number and frequency of blood transfusions. In fact, 2 patients (10%) who tested positive for anti-HCV antibodies had never received transfusions. Patients with anti-HCV antibodies had significantly abnormal liver functions, such as higher levels of serum aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) and lower levels of serum albumin, compared with patients without anti-HCV antibodies (P = .021, .017, and .004, respectively). However, there were also significant correlations between iron status as indicated by transferrin saturation or serum ferritin levels and SGOT, SGPT, and gamma-glutamyltransferase (GGT) levels. Moreover, abnormal liver function as represented by elevated levels of SGOT, SGPT, GGT, and serum alkaline phosphatase was observed more frequently in patients with iron overload than in patients with a lower degree of iron burden. The presence of HCV did not alter the effects of iron overload on liver function. The findings suggest that both HCV and iron overload are the main causes of abnormal liver function in Thai patients with thalassemia. The treatment of both problems, if coexisting in patients with thalassemia, is required to prevent progression to chronic liver disease.

Entities:  

Mesh:

Year:  2003        PMID: 14686498     DOI: 10.1007/BF02983565

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

Review 1.  To C or not to C: these are the questions.

Authors:  H J Alter
Journal:  Blood       Date:  1995-04-01       Impact factor: 22.113

Review 2.  Hepatitis C: an update on the silent epidemic.

Authors:  S A Sarbah; Z M Younossi
Journal:  J Clin Gastroenterol       Date:  2000-03       Impact factor: 3.062

3.  Infection in thalassemia: a retrospective study of 1,018 patients with beta-thalassemia/Hb E disease.

Authors:  S Issaragrisil; W Wanachiwanawin; K Bhuripanyo; Y Benjasuratwong; A Piankijagum; P Wasi
Journal:  Birth Defects Orig Artic Ser       Date:  1987

4.  Deaths in beta-thalassemia/Hb E patients secondary to infections.

Authors:  S Fucharoen; A Piankijagum; P Wasi
Journal:  Birth Defects Orig Artic Ser       Date:  1987

5.  Recommendations for measurement of serum iron in human blood.

Authors: 
Journal:  Br J Haematol       Date:  1978-02       Impact factor: 6.998

6.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay.

Authors:  M E Lai; S De Virgilis; F Argiolu; P Farci; A P Mazzoleni; V Lisci; M Rapicetta; M G Clemente; P Nurchis; M Arnone
Journal:  J Pediatr Gastroenterol Nutr       Date:  1993-05       Impact factor: 2.839

8.  A study of hepatitis B and C prevalence and liver function in multiply transfused thalassemic and their parents.

Authors:  T N Williams; B Wonke; S M Donohue
Journal:  Indian Pediatr       Date:  1992-09       Impact factor: 1.411

9.  IgM antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of liver disease in patients with acute or chronic hepatitis C.

Authors:  R Nagayama; K Miyake; F Tsuda; H Okamoto
Journal:  J Med Virol       Date:  1994-03       Impact factor: 2.327

10.  Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg.

Authors:  H Iizuka; K Ohmura; A Ishijima; K Satoh; T Tanaka; F Tsuda; H Okamoto; Y Miyakawa; M Mayumi
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

View more
  6 in total

1.  Metabolic investigations in patients with hepatitis B and C.

Authors:  Abdul Aziz Mastoi; Bikha Ram Devrajani; Syed Zulfiquar Ali Shah; Qasim Rohopoto; Sikander Ali Memon; Marya Baloch; Ghulam Ali Qureshi; Waqas Sami
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

2.  Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Gia L Tyson; Jennifer R Kramer; Zhigang Duan; Jessica A Davila; Peter A Richardson; Hashem B El-Serag
Journal:  Hepatology       Date:  2013-07-01       Impact factor: 17.425

3.  A Pilot Study on Pain and the Upregulation of Myoglobin through Low-frequency and High-amplitude Electrical Stimulation-induced Muscle Contraction.

Authors:  Lim-Kyu Lee; Ju-Hyun Kim; Mee-Young Kim; Jeong-Uk Lee; Seung-Min Yang; Hye-Joo Jeon; Won-Deok Lee; Ji-Woong Noh; Taek-Yong Kwak; Sung-Ho Jang; Tae-Hyun Lee; Ju-Young Kim; Junghwan Kim
Journal:  J Phys Ther Sci       Date:  2014-07-30

4.  Evaluation of hepatitis C, hepatitis B, and HIV virus Serology pandemic in thalassemia patients of Shahid Mohammadi Hospital of Bandar Abbas, Iran.

Authors:  Mohammad Aminianfar; Farrokh Khani; Iman Ghasemzadeh
Journal:  Electron Physician       Date:  2017-03-25

5.  Trend in Prevalence of Hepatitis C Virus Infection among β-thalassemia Major Patients: 10 Years of Experience in Iran.

Authors:  Maryam Jafroodi; Ali Davoudi-Kiakalayeh; Zahra Mohtasham-Amiri; Ali Akbar Pourfathollah; Azade Haghbin
Journal:  Int J Prev Med       Date:  2015-09-08

6.  Assessment Hepatomegaly and liver Enzymes in 100 Patients with beta Thalassemia Major in Mashhad, Iran.

Authors:  H Hashemizadeh; R Noori; Sh Kolagari
Journal:  Iran J Ped Hematol Oncol       Date:  2012-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.